Edwards Lifesciences Corporation (EW) scored on five pillars from its reported financial statements, and ranked against 212 Healthcare companies.
Edwards Lifesciences Corporation (EW) scores 5.7 out of 10 as of , computed from its reported financial statements. That reads as solid quality. The reading rests on solvency, and growth is what holds it back.
Data provided by Twelve Data. Scores are computed by Lemma Analysis from reported financials.
We cannot judge Edwards Lifesciences Corporation yet, because fewer than five years had both a return on capital and a cost of capital we could measure. This is not a “no”.
Quantitative signs of a moat, read from the filed statements. This is not a judgement of where it comes from (brand, network effects, switching costs). How Lemma measures a moat →
On the filings behind it, Edwards Lifesciences Corporation earns 5.7 out of 10 for business quality as of October 19, 2026. That is solid quality on our scale. A solid reading is a respectable business with clear strengths and at least one area that falls short of the best in its field. The figure is a weighted average of five pillars, each scored from 0 to 10 against sector-aware benchmarks from reported statements.
Ranked with the 212 Healthcare companies Lemma publishes, the score sits at the 68th percentile, in the better half of its peers. For reference, the middle of the group scores 4.4 and a company needs 6.0 to reach its top quarter, which leaves Edwards Lifesciences Corporation above the median.
Edwards Lifesciences Corporation’s profitability score is 5.7 out of 10 (average). Against a median of 2.7 among 210 Healthcare companies, that is well above the group and the 77th percentile. An average profitability reading usually means the company earns a fair return without obvious pricing power, so the other pillars decide more of the story.
Solvency scores 9.8 out of 10, which reads as strong. The median across 150 Healthcare companies is 6.5, so Edwards Lifesciences Corporation is well above its peers on this pillar and ranks at the 92nd percentile. A high solvency score means leverage is modest relative to earnings and cash flow, which gives management room to act in a bad year.
On growth, Edwards Lifesciences Corporation scores 2.3, a weak reading. Its peers have a median of 4.9 across 107 Healthcare companies, which places it well below them, at the 23rd percentile. When growth is this low the question is whether it is a pause or a trend, and the history behind the filings is the place to look.
On efficiency, Edwards Lifesciences Corporation scores 5.6, an average reading. Its peers have a median of 6.0 across 200 Healthcare companies, which places it in line with them, at the 41st percentile. Efficiency near the median says the operation is neither unusually lean nor unusually capital hungry.
Predictability scores 5.0 out of 10, which reads as average. The median across 207 Healthcare companies is 3.4, so Edwards Lifesciences Corporation is well above its peers on this pillar and ranks at the 68th percentile. Middling predictability suggests some volatility in the record, enough to read the other pillars with a little caution.
This is a lopsided profile. Solvency scores 9.8 but growth only 2.3, a gap of 7.5 points, so the overall hides a business that is excellent in one respect and weak in another. A solvency lead means the balance sheet is the company’s strongest asset, a cushion that buys time when trading gets harder. A growth shortfall often comes with size or a maturing market, and is less of a concern if the other pillars are strong.
Of everything that could lift Edwards Lifesciences Corporation’s score, growth matters most. Bringing it up to the 4.9 median of Healthcare companies would take the overall from 5.7 to roughly 6.2. All five pillars could be scored, so the overall uses the full set of weights out of 100: profitability 25, solvency 20, growth 20, efficiency 15, predictability 20.
These are the Healthcare companies closest to Edwards Lifesciences Corporation in market value. Each has its own page scored on the same five pillars, so the comparison is like for like.
How much profit the company generates from its capital and sales.
The company’s ability to service debt and meet its obligations.
How fast revenue, earnings and cash flow are compounding.
How well assets and earnings convert into cash and output.
How stable and consistent results have been over time.
Each metric is scored from 0 to 10 against sector-aware benchmarks, where higher is better. Metrics roll up into five pillars, and the pillars combine into the overall score using the weights shown. Sector-sensitive metrics are judged relative to peers in the same sector.
This score is a systematic, backward-looking read of reported fundamentals. It does not judge valuation, management quality, competitive moat, or future prospects, and can be distorted by one-off items or unusual accounting. Treat it as a starting point, not a recommendation.
Educational only. Not investment advice.
On this reading Edwards Lifesciences Corporation scores 5.7 out of 10, which reads as solid quality. Its strongest pillar is solvency, its weakest is growth. Quality is not the same as a good investment: the score says nothing about the price you would pay.
Edwards Lifesciences Corporation ranks at the 68th percentile of the 212 Healthcare companies Lemma publishes a score for. The median there is 4.4 and the top quarter starts at 6.0, against Edwards Lifesciences Corporation’s 5.7.
Five pillars, each scored from 0 to 10 against sector-aware benchmarks and then weighted into one overall reading: profitability, solvency, growth, efficiency and predictability. Everything comes from reported financials, and nothing comes from price, sentiment or forecasts.
This page last changed on October 19, 2026. The score moves with the financial statements, so the page changes when a new filing moves the reading rather than on a schedule. Live figures for EW are in the app.
No. Quality and valuation are separate questions, and a good business at the wrong price is still a bad purchase. Score the business here, then price it with a DCF you control.
Inside Lemma Analysis the same five pillars run on every company we cover, with the metrics behind each one, current fundamentals, a DCF you control and a watchlist that tells you when the price catches up.
Free to start · No credit card